A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of twice daily oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic response in pediatric patients with relapsed or refractory leukemia - ND

OVARTIS FARMA0 sites22 target enrollmentNovember 3, 2009

Conditionsrelapsed or refractory leukemias in paediatric patients MedDRA version: 12.0Level: LLTClassification code 10060558Term: Acute myeloid leukemia recurrent

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: relapsed or refractory leukemias in paediatric patients
Sponsor: OVARTIS FARMA
Enrollment: 22
Status: Active, not recruiting
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

November 3, 2009

End Date

TBD

Last Updated

11 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

OVARTIS FARMA

Eligibility Criteria

Inclusion Criteria

•1\. Patients must have a documented diagnosis of one of the following leukemias: MLL\-rearranged ALL, refractory to standard induction treatment or in first or subsequent relapse FLT3\-mutated AML refractory to standard induction (after failure of at least 2 different induction chemotherapy regimens) or refractory to re\-induction at 1st relapse (after failure of the first re\-induction course), or in second or greater relapse 2\. Patients must be less than 18 years of age and ≥3 months of age. 3\. Patients must have a Lansky/Karnofsky performance status ≥ 60\. 4\. Patients must have the following laboratory values reflecting appropriate organ function: AST and ALT ≤ 5x Upper Limit of Normal (ULN), Serum Bilirubin ≤ 1\.5 x ULN, Serum Creatinine ≤ 2 x ULN. 5\. Patients must have an expected survival of greater than 8 weeks.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) no
•F.1\.2\.1 Number of subjects for this age range
•F.1\.3 Elderly (\>\=65 years) no
•F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

•1\. Patients with symptomatic leukemic CNS involvement. 2\. Patients with isolated extramedullary leukemia. 3\. Patients must have recovered from prior cytotoxic chemotherapy, and a minimum wash\-out time of previous chemotherapy of 72 hours should be taken into account. 4\. Patients who had prior allogeneic, syngeneic or autologous bone marrow or stem cell transplant less than 2 months from Day 1 5\. Patients who have received any investigational agent within 30 days or 5 half lives, whichever is greater, prior to Day 1\. An investigational agent is an agent with no approved medical uses in adults or pediatrics. 6\. Patients who have had prior treatment with a FLT3 inhibiting drug or investigational agent. 7\. Use of CYP3A4/5 enzyme inducing or inhibiting drugs or herbal supplements while on study treatment 8\. The use of corticosteroids while on study drug 9\. Patients who have had any surgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin or bone marrow biopsy), within 14 days of Day 1\. 10\. Patients with any other known disease concurrent severe and/or uncontrolled medical condition (e.g. cardiovascular disease including congestive heart failure or active uncontrolled infection) which could compromise participation in the study. 11\. Patients with an abnormal chest X\-ray and/or any pulmonary infiltrate including those suspected to be of infectious origin. In particular, patients with resolution of clinical symptoms of pulmonary infection but with residual pulmonary infiltrates on chest x\-ray are not eligible until pulmonary infiltrates have completely resolved. 12\. Patients with known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of midostaurin, including active graft\-versus\-host disease of the liver or the gut. 13\. Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis. 14\. Patients with a left ventricular shortening fraction \< 27% as determined by MUGA scan or echocardiogram 15\. Patients with abnormal ECG including: QTcF ≥ 450 ms, PR ≥200 msec, QRS complex ≥110 msec, at screening Any cardiac conduction abnormality Any morphologic abnormality Any ST/T wave abnormality Any atrial or ventricular arrhythmia 16\. Female patients who are pregnant or breast feeding or patients of reproductive potential not employing an effective method of birth control. Barrier contraceptives must be used throughout the trial by both sexes, if applicable. 17\. Males of reproductive potential unwilling to comply with contraceptive requirements 18\. Patients/parents unwilling or unable to comply with the protocol